Format

Send to

Choose Destination
See comment in PubMed Commons below
Ecancermedicalscience. 2013 Mar 20;7:297. doi: 10.3332/ecancer.2013.297. Print 2013.

Clinical evidence for the use of aspirin in the treatment of cancer.

Author information

  • 1MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, UK and.

Abstract

Although the anti-cancer effects of aspirin were first identified in pre-clinical models four decades ago, a clear role for the drug in either the prevention or treatment of cancer has not been established. Concerns about toxicity, particularly major haemorrhage, and a lack of randomised evidence demonstrating efficacy have limited its use in primary prevention; there was also doubt that a simple aspirin could have a significant therapeutic effect against established malignancy. Three new pieces of evidence: a series of meta-analyses focusing on cancer outcomes from randomised-controlled trials designed to assess the vascular benefits of daily aspirin; the first positive results from a randomised-controlled trial designed to demonstrate that aspirin can prevent cancer in those with a hereditary predisposition; and observational data showing that aspirin use after a cancer diagnosis improves both cancer mortality and overall survival; have led to a re-evaluation of aspirin as a potential anti-cancer agent both for the prevention and treatment of cancer.

KEYWORDS:

aspirin; cancer; mechanisms; toxicity; treatment

PMID:
23589726
PMCID:
PMC3622409
DOI:
10.3332/ecancer.2013.297
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center